EXEL/IPN.PA/BMY—Opdivo/Cabometyx statsig superior PFS/OS to Sutent monotharpy in first-line RCC in CHECKMATE-9ER study: https://finance.yahoo.com/news/bristol-myers-squibb-exelixis-announce-105900676.html A tweet says that the HR for PFS was 0.51, and the HR for OS was 0.60 (https://twitter.com/BioSyncopation/status/1252216825603072000 ), although these data are not in the above PR. As I’m typing… EXEL +24%; IPN.PA +6%; BMY +2%.